Back to top Open menu arrow
Download Reprints
Sections
METHODS RESULTS DISCUSSION Clinical Points
The Journal of Clinical Psychiatry The Journal of Clinical Psychiatry

The Journal of
Clinical Psychiatry
Access icon

Meta-Analysis Focus on Suicide January 18, 2022

Decreases in Suicidality Following Psychedelic Therapy: A Meta-Analysis of Individual Patient Data Across Clinical Trials

Richard J. Zeifman, MA; Dengdeng Yu, PhD; Nikhita Singhal, MD; Guan Wang, HBSc; Sandeep M. Nayak, MD; Cory R. Weissman, MD

J Clin Psychiatry 2022;83(2):21r14057

ABSTRACT

Objective: Suicide is a global health concern, and innovative interventions that target suicidality are needed. While psychedelic therapy shows promise for a range of mental health concerns, including suicidality, not all psychedelic therapy trials have published their suicidality results and no meta-analysis has been published on the topic. Therefore, we completed the first meta-analysis of patient-level data on the effects of psychedelics on suicidality.

Data Sources: We conducted a systematic search of MEDLINE, PsycINFO, and PubMed for all psychedelic therapy clinical trials (last search: November 5, 2020).

Study Selection: We identified all psychedelic therapy trials that included a measure or measure-item that assesses suicidality.

Data Extraction: Suicidality data were requested from study authors and extracted using a data extraction form developed for this study.

Results: We identified 8, and successfully collected data from 7, relevant trials. Analysis of standardized mean differences (SMDs) indicated that, relative to baseline, psychedelic therapy was associated with large effect sizes for acute (80–240 min) and sustained (1 day, 1–8 weeks, and 3–4 months) decreases in suicidality (SMD range = −1.48 to −2.36; 95% CI range, −4.30 to 0.23). At 6 months, the effect size was medium (SMD = −0.65; 95% CI, −1.14 to −0.16). Reductions in suicidality were significant at all time points except for 7–8 weeks. Acute and post-acute elevations in suicidality were rare (6.5% and 3.0%, respectively).

Conclusions: Limitations include heterogeneous samples and interventions, as well as limited sample size and number of studies. Results provide preliminary support for the safety of psychedelic therapy and its positive effect on suicidality. Controlled trials that specifically evaluate the effect of psychedelic therapy on suicidality may be warranted.

Continue Reading...

Did you know members enjoy unlimited free PDF downloads as part of their subscription? Subscribe today for instant access to this article and our entire library in your preferred format. Alternatively, you can purchase the PDF of this article individually.

Subscribe Now

Already a member? Login

Purchase PDF for $40

Members enjoy free PDF downloads on all articles. Join today

  1. World Health Organization. Suicide: Key facts. World Health Organization website. https://www.who.int/en/news-room/fact-sheets/detail/suicide. 2019. Accessed February 20, 2021
  2. Bostwick JM, Pabbati C, Geske JR, et al. Suicide attempt as a risk factor for completed suicide: even more lethal than we knew.Am J Psychiatry. 2016;173(11):1094–1100. PubMed CrossRef
  3. Hubers AAM, Moaddine S, Peersmann SHM, et al. Suicidal ideation and subsequent completed suicide in both psychiatric and non-psychiatric populations: a meta-analysis.Epidemiol Psychiatr Sci. 2018;27(2):186–198. PubMed CrossRef
  4. Substance Abuse and Mental Health Services Administration. Key substance use and mental health indicators in the United States: Results from the 2019 National Survey on Drug Use and Health (HHS Publication No. PEP20-07-01-001, NSDUH Series H-55). Rockville, MD: Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health Services Administration. SAMHSA website. https://www.samhsa.gov/data/. 2020. Accessed February 20, 2021
  5. Dold M, Bartova L, Fugger G, et al. Major depression and the degree of suicidality: results of the European Group for the Study of Resistant Depression (GSRD).Int J Neuropsychopharmacol. 2018;21(6):539–549. PubMed CrossRef
  6. Dutta R, Ball HA, Siribaddana SH, et al. Genetic and other risk factors for suicidal ideation and the relationship with depression.Psychol Med. 2017;47(14):2438–2449. PubMed CrossRef
  7. Pigeon WR, Pinquart M, Conner K. Meta-analysis of sleep disturbance and suicidal thoughts and behaviors.J Clin Psychiatry. 2012;73(9):e1160–e1167. PubMed CrossRef
  8. Du L, Shi HY, Yu HR, et al. Incidence of suicide death in patients with cancer: a systematic review and meta-analysis.J Affect Disord. 2020;276:711–719. PubMed CrossRef
  9. Klaassen Z, Wallis CJD, Chandrasekar T, et al. Cancer diagnosis and risk of suicide after accounting for prediagnosis psychiatric care: a matched-cohort study of patients with incident solid-organ malignancies.Cancer. 2019;125(16):2886–2895. PubMed CrossRef
  10. Kolva E, Hoffecker L, Cox-Martin E. Suicidal ideation in patients with cancer: A systematic review of prevalence, risk factors, intervention and assessment. Palliat Support Care. 2020;18(2):206–219. PubMed CrossRef
  11. Klonsky ED, May AM, Saffer BY. Suicide, suicide attempts, and suicidal ideation. Annu Rev Clin Psychol. 2016;12(1):307–330. PubMed CrossRef
  12. DeCou CR, Comtois KA, Landes SJ. Dialectical behavior therapy is effective for the treatment of suicidal behavior: a meta-analysis. Behav Ther. 2019;50(1):60–72. PubMed CrossRef
  13. Leavey K, Hawkins R. Is cognitive behavioural therapy effective in reducing suicidal ideation and behaviour when delivered face-to-face or via e-health? A systematic review and meta-analysis. Cogn Behav Ther. 2017;46(5):353–374. PubMed CrossRef
  14. Hawton K, Witt KG, Salisbury TLT, et al. Psychosocial interventions following self-harm in adults: a systematic review and meta-analysis. Lancet Psychiatry. 2016;3(8):740–750. PubMed CrossRef
  15. Kellner CH, Fink M, Knapp R, et al. Relief of expressed suicidal intent by ECT: a consortium for research in ECT study. Am J Psychiatry. 2005;162(5):977–982. PubMed CrossRef
  16. Read J, Kirsch I, McGrath L. Electroconvulsive therapy for depression: a review of the quality of ECT versus sham ECT trials and meta-analyses. Ethical Hum Psychol Psychiatry. 2019;21(2):64–103. CrossRef
  17. Hengartner MP, Amendola S, Kaminski JA, et al. Suicide risk with selective serotonin reuptake inhibitors and other new-generation antidepressants in adults: a systematic review and meta-analysis of observational studies. J Epidemiol Community Health. 2021;75(6):523–530. PubMed CrossRef
  18. Hengartner MP, Plöderl M. Newer-generation antidepressants and suicide risk in randomized controlled trials: a re-analysis of the FDA database. Psychother Psychosom. 2019;88(4):247–248. PubMed CrossRef
  19. Witt K, Potts J, Hubers A, et al. Ketamine for suicidal ideation in adults with psychiatric disorders: a systematic review and meta-analysis of treatment trials. Aust N Z J Psychiatry. 2020;54(1):29–45. PubMed CrossRef
  20. Luu B, Rice E, Goldin P. Ketamine in the treatment of major depressive disorder. J Nurse Pract. 2020;16(3):228–231. CrossRef
  21. Strong CE, Kabbaj M. On the safety of repeated ketamine infusions for the treatment of depression: effects of sex and developmental periods. Neurobiol Stress. 2018;9:166–175. PubMed CrossRef
  22. Del Matto L, Muscas M, Murru A, et al. Lithium and suicide prevention in mood disorders and in the general population: a systematic review. Neurosci Biobehav Rev. 2020;116:142–153. PubMed CrossRef
  23. Zalsman G, Hawton K, Wasserman D, et al. Suicide prevention strategies revisited: 10-year systematic review. Lancet Psychiatry. 2016;3(7):646–659. PubMed CrossRef
  24. Ahmadi J, Jahromi MS, Ehsaei Z. The effectiveness of different singly administered high doses of buprenorphine in reducing suicidal ideation in acutely depressed people with co-morbid opiate dependence: a randomized, double-blind, clinical trial. Trials. 2018;19(1):462. PubMed CrossRef
  25. Yovell Y, Bar G, Mashiah M, et al. Ultra-low-dose buprenorphine as a time-limited treatment for severe suicidal ideation: a randomized controlled trial. Am J Psychiatry. 2016;173(5):491–498. PubMed CrossRef
  26. Kawashima Y, Yonemoto N, Inagaki M, et al. Interventions to prevent suicidal behavior and ideation for patients with cancer: a systematic review. Gen Hosp Psychiatry. 2019;60:98–110. PubMed CrossRef
  27. Fox KR, Huang X, Guzmán EM, et al. Interventions for suicide and self-injury: a meta-analysis of randomized controlled trials across nearly 50 years of research. Psychol Bull. 2020;146(12):1117–1145. PubMed CrossRef
  28. National Action Alliance for Suicide Prevention. Research Prioritization Task Force: A Prioritized Research Agenda for Suicide Prevention: An Action Plan to Save Lives. Rockville, MD: National Institute of Mental Health and Research Prioritization Task Force; 2014.
  29. Stanley B, Mann JJ. The need for innovation in health care systems to improve suicide prevention. JAMA Psychiatry. 2020;77(1):96–98. PubMed CrossRef
  30. Johnson MW, Hendricks PS, Barrett FS, et al. Classic psychedelics: an integrative review of epidemiology, therapeutics, mystical experience, and brain network function. Pharmacol Ther. 2019;197:83–102. PubMed CrossRef
  31. Andersen KAA, Carhart-Harris R, Nutt DJ, et al. Therapeutic effects of classic serotonergic psychedelics: a systematic review of modern-era clinical studies. Acta Psychiatr Scand. 2021;143(2):101–118. PubMed CrossRef
  32. Carhart-Harris RL, Bolstridge M, Day CMJ, et al. Psilocybin with psychological support for treatment-resistant depression: six-month follow-up. Psychopharmacology (Berl). 2018;235(2):399–408. PubMed CrossRef
  33. Davis AK, Barrett FS, May DG, et al. Effects of psilocybin-assisted therapy on major depressive disorder: a randomized clinical trial. JAMA Psychiatry. 2021;78(5):481–489. PubMed CrossRef
  34. Palhano-Fontes F, Barreto D, Onias H, et al. Rapid antidepressant effects of the psychedelic ayahuasca in treatment-resistant depression: a randomized placebo-controlled trial. Psychol Med. 2019;49(4):655–663. PubMed CrossRef
  35. Sanches RF, de Lima Osório F, Dos Santos RG, et al. Antidepressant effects of a single dose of ayahuasca in patients with recurrent depression: A SPECT study. J Clin Psychopharmacol. 2016;36(1):77–81. PubMed CrossRef
  36. Agin-Liebes GI, Malone T, Yalch MM, et al. Long-term follow-up of psilocybin-assisted psychotherapy for psychiatric and existential distress in patients with life-threatening cancer. J Psychopharmacol. 2020;34(2):155–166. PubMed CrossRef
  37. Griffiths RR, Johnson MW, Carducci MA, et al. Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: a randomized double-blind trial. J Psychopharmacol. 2016;30(12):1181–1197. PubMed CrossRef
  38. Grob CS, Danforth AL, Chopra GS, et al. Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer. Arch Gen Psychiatry. 2011;68(1):71–78. PubMed CrossRef
  39. Ross S, Bossis A, Guss J, et al. Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial. J Psychopharmacol. 2016;30(12):1165–1180. PubMed CrossRef
  40. Zeifman RJ, Singhal N, Breslow L, et al. On the relationship between classic psychedelics and suicidality: a systematic revie ACS Pharmacol Transl Sci. 2021;4(2):436–451. PubMed CrossRef
  41. Zeifman RJ, Palhano-Fontes F, Hallak J, et al. The impact of ayahuasca on suicidality: results from a randomized controlled trial. Front Pharmacol. 2019;10:1325. PubMed CrossRef
  42. Ross S, Agin-Liebes G, Lo S, et al. Acute and sustained reductions in loss of meaning and suicidal ideation following psilocybin-assisted psychotherapy for psychiatric and existential distress in life-threatening cancer. ACS Pharmacol Transl Sci. 2021;4(2):553–562. PubMed CrossRef
  43. Zeifman RJ, Singhal N, Dos Santos RG, et al. Rapid and sustained decreases in suicidality following a single dose of ayahuasca among individuals with recurrent major depressive disorder: results from an open-label trial. Psychopharmacology (Berl). 2021;238(2):453–459. PubMed CrossRef
  44. Moher D, Liberati A, Tetzlaff J, et al; PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6(7):e1000097. PubMed CrossRef
  45. Nichols DE. Pharmacol Rev. 2016;68(2):264–355. PubMed CrossRef
  46. Higgins JPT, Sterne JAC, Savović J, et al. A revised tool for assessing risk of bias in randomized trials. In: Chandler J, McKenzie J, Boutron I, et al, eds. Cochrane Database of Systematic Reviews. 10th ed. Cochrane Methods; 2016.
  47. Deeks JJ, Dinnes J, D’Amico R, et al; International Stroke Trial Collaborative Group; European Carotid Surgery Trial Collaborative Group. Evaluating non-randomised intervention studies. Health Technol Assess. 2003;7(27):iii–x, 1–173. PubMed CrossRef
  48. Romeo B, Karila L, Martelli C, et al. Efficacy of psychedelic treatments on depressive symptoms: A meta-analysis. J Psychopharmacol. 2020;34(10):1079–1085. PubMed CrossRef
  49. Higgins JPT, Green S. Cochrane Handbook for Systematic Reviews of Interventions 4.2.6. Chichester, UK: John Wiley & Sons; 2006.
  50. Zisook S, Trivedi MH, Warden D, et al. Clinical correlates of the worsening or emergence of suicidal ideation during SSRI treatment of depression: an examination of citalopram in the STAR*D study. J Affect Disord. 2009;117(1-2):63–73. PubMed CrossRef
  51. Gasser P, Holstein D, Michel Y, et al. Safety and efficacy of lysergic acid diethylamide-assisted psychotherapy for anxiety associated with life-threatening dis J Nerv Ment Dis. 2014;202(7):513–520. PubMed CrossRef
  52. Anderson BT, Danforth A, Daroff PR, et al. Psilocybin-assisted group therapy for demoralized older long-term AIDS survivor men: an open-label safety and feasibility pilot study. EClinicalMedicine. 2020;27:100538. PubMed CrossRef
  53. Beck AT, Brown GK, Steer RA. Beck Depression Inventory-II. San Antonio, TX: The Psychological Corporation; 1996.
  54. Posner K, Brown GK, Stanley B, et al. The Columbia-Suicide Severity Rating Scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults. Am J Psychiatry. 2011;168(12):1266–1277. PubMed CrossRef
  55. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960;23(1):56–62. PubMed CrossRef
  56. Montgomery SA, Åsberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry. 1979;134(4):382–389. PubMed CrossRef
  57. Rush AJ, Trivedi MH, Ibrahim HM, et al. The 16-Item Quick Inventory of Depressive Symptomatology (QIDS), clinician rating (QIDS-C), and self-report (QIDS-SR): a psychometric evaluation in patients with chronic major depression. Biol Psychiatry. 2003;54(5):573–583. PubMed CrossRef
  58. Johnson MW, Griffiths RR, Hendricks PS, et al. The abuse potential of medical psilocybin according to the 8 factors of the Controlled Substances Act. Neuropharmacology. 2018;142:143–166. PubMed CrossRef
  59. Nutt DJ, King LA, Phillips LD; Independent Scientific Committee on Drugs. Drug harms in the UK: a multicriteria decision analysis. Lancet. 2010;376(9752):1558–1565. PubMed CrossRef
  60. Garcia-Romeu A, Richards WA. Current perspectives on psychedelic therapy: use of serotonergic hallucinogens in clinical interventions. Int Rev Psychiatry. 2018;30(4):291–316. PubMed CrossRef
  61. Bergfeld IO, Mantione M, Figee M, et al. Treatment-resistant depression and suicidality. J Affect Disord. 2018;235:362–367. PubMed CrossRef
  62. Weissman CR, Hadas I, Yu D, et al. Predictors of change in suicidal ideation across treatment phases of major depressive disorder: analysis of the STAR*D data. Neuropsychopharmacology. 2021;46(7):1293–1299. PubMed CrossRef
  63. Johnson M, Richards W, Griffiths R. Human hallucinogen research: guidelines for safety. J Psychopharmacol. 2008;22(6):603–620. PubMed CrossRef
  64. Hamill J, Hallak J, Dursun SM, et al. Ayahuasca: Psychological and physiologic effects, pharmacology and potential uses in addiction and mental illness. Curr Neuropharmacol. 2019;17(2):108–128. PubMed CrossRef
  65. Carhart-Harris RL, Roseman L, Haijen E, et al. Psychedelics and the essential importance of J Psychopharmacol. 2018;32(7):725–731. PubMed CrossRef
  66. Galvão-Coelho NL, de Menezes Galvão AC, de Almeida RN, et al. Changes in inflammatory biomarkers are related to the antidepressant effects of Ayahuasca. J Psychopharmacol. 2020;34(10):1125–1133. PubMed CrossRef
  67. Nobile B, Olié E, Courtet P. Commentary: Psychedelic Psychiatry’s Brave New World. Front Psychiatry. 2020;11:594077. PubMed CrossRef
  68. Dos Santos RG, Hallak JEC. Therapeutic use of serotoninergic hallucinogens: a review of the evidence and of the biological and psychological mechanisms. Neurosci Biobehav Rev. 2020;108:423–434. PubMed CrossRef
  69. Carhart-Harris RL, Kaelen M, Bolstridge M, et al. The paradoxical psychological effects of lysergic acid diethylamide (LSD). Psychol Med. 2016;46(7):1379–1390. PubMed CrossRef
  70. Griffiths RR, Johnson MW, Richards WA, et al. Psilocybin-occasioned mystical-type experience in combination with meditation and other spiritual practices produces enduring positive changes in psychological functioning and in trait measures of prosocial attitudes and behaviors. J Psychopharmacol. 2018;32(1):49–69. PubMed CrossRef
  71. Lyons T, Carhart-Harris RL. More realistic forecasting of future life events after psilocybin for treatment-resistant depression. Front Psychol. 2018;9:1721. PubMed CrossRef
  72. Davis AK, Averill LA, Sepeda ND, et al. Psychedelic treatment for trauma-related psychological and cognitive impairment among US Special Operations Forces Veterans. Chronic Stress (Thousand Oaks). 2020;4:2470547020939564. PubMed CrossRef
  73. Soler J, Elices M, Dominguez-Clavé E, et al. Four weekly ayahuasca sessions lead to increases in “acceptance” capacities: a comparison study with a standard 8-week mindfulness training program. Front Pharmacol. 2018;9:224. PubMed CrossRef
  74. Watts R, Day C, Krzanowski J, et al. Patients’ accounts of increased “connectedness” and “acceptance” after psilocybin for treatment-resistant depression. J Humanist Psychol. 2017;57(5):520–564. CrossRef
  75. Wolff M, Evens R, Mertens LJ, et al. Learning to let go: a cognitive-behavioral model of how psychedelic therapy promotes acceptance. Front Psychiatry. 2020;11:5. PubMed CrossRef
  76. Zeifman RJ, Wagner AC, Watts R, et al. Post-psychedelic reductions in experiential avoidance are associated with decreases in depression severity and suicidal ideation. Front Psychiatry. 2020;11:782. PubMed CrossRef
  77. Zeifman RJ, Wagner AC. Exploring the case for research on incorporating psychedelics within interventions for borderline personality disorder. J Contextual Behav Sci. 2020;15:1–11. CrossRef
  78. Heuschkel K, Kuypers KPC. Depression, mindfulness, and psilocybin: possible complementary effects of mindfulness meditation and psilocybin in the treatment of depression. a Review. Front Psychiatry. 2020;11:224. PubMed CrossRef
  79. Payne JE, Chambers R, Liknaitzky P. Combining psychedelic and mindfulness interventions: Synergies to inform clinical practice. ACS Pharmacol Transl Sci. 2021;4(2):416–423. PubMed CrossRef
  80. Meyer RE, Salzman C, Youngstrom EA, et al. Suicidality and risk of suicide—definition, drug safety concerns, and a necessary target for drug development: a consensus statement. J Clin Psychiatry. 2010;71(08):e1–e21. PubMed CrossRef
  81. Domany Y, Bleich-Cohen M, Tarrasch R, et al. Repeated oral ketamine for out-patient treatment of resistant depression: randomised, double-blind, placebo-controlled, proof-of-concept study. Br J Psychiatry. 2019;214(1):20–26. PubMed CrossRef
  82. Desseilles M, Perroud N, Guillaume S, et al. Is it valid to measure suicidal ideation by depression rating scales? J Affect Disord. 2012;136(3):398–404. PubMed CrossRef
  83. Beck AT, Steer RA, Ranieri WF. Scale for Suicide Ideation: psychometric properties of a self-report version. J Clin Psychol. 1988;44(4):499–505. PubMed CrossRef
  84. Nock MK, Park JM, Finn CT, et al. Measuring the suicidal mind: implicit cognition predicts suicidal behavior. Psychol Sci. 2010;21(4):511–517. PubMed CrossRef
  85. Ballard ED, Gilbert JR, Wusinich C, et al. New methods for assessing rapid changes in suicide risk. Front Psychiatry. 2021;12:598434. PubMed CrossRef
  86. Carhart-Harris RL, Wagner AC, Agrawal M, et al. Can pragmatic research, real-world data and digital technologies aid the development of psychedelic medicine? J Psychopharmacol. 2021;2698811211008567. PubMed CrossRef
Purchase PDF for $40

Members enjoy free PDF downloads on all articles. Join today

Save Save

Share Share

Cite Cite

Vol 85 • 2024 • Number 3

Read the Current Issue

Editorial

Focus on Women’s Mental Health: Twenty Years and Counting

Original Research

Esmethadone in Patients With Major Depressive Disorder and Inadequate Response to Standard Antidepressants

Commentary

Can Our Collective Experiences As Clinicians Improve Mental Health Care?

Original Research

Prescription Opioid Use Disorder in US Adults Reporting Prescription Opioid Use

Original Research

Symptomatic Disorders Comorbid with Borderline Personality Disorder Over Time

Original Research

Aripiprazole Lauroxil Initiation Regimens
View current Issue

Celebrating
85 Years

Read the Journal of Clinical Psychiatry

Subscribe to read
more articles

Subscribe